|
시장보고서
상품코드
2075351
간질성 방광염 치료제 시장 : 약제 클래스별, 유형별, 투여 경로별, 유통 채널별, 지역별Interstitial Cystitis Drugs Market, By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
간질성 방광염 치료제 시장은 2026년에 2억 8,760만 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 4억 6,480만 달러에 달할 것으로 전망되고 있습니다. 2026-2033년에는 CAGR 7.1%로 성장할 것으로 예측됩니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 2억 8,760만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 7.10% | 2033년 시장 규모 예측 : | 4억 6,480만 달러 |
간질성 방광염(IC)은 통증성 방광 증후군이라고도 불리며, 방광 압박감, 방광통, 때로는 골반통을 유발하는 만성질환입니다. 그 통증은 경미한 불편감부터 심한 통증까지 다양합니다. 방광은 가득 찰 때까지 팽창한 뒤, 골반 신경을 통해 뇌에 배뇨 신호를 보냅니다. 간질성 방광염(IC)의 경우, 이러한 신호가 흐트러지기 때문에 환자는 일반인보다 더 자주, 그리고 소량의 소변을 보고 싶은 느낌을 받습니다. IC는 주로 여성에게 발병하며, 삶의 질에 장기적인 영향을 미칠 수 있습니다. 근본적인 치료법은 없지만, 약물 요법이나 그 밖의 치료법을 통해 증상이 완화될 수 있는 경우가 있습니다.
IC에는 두 가지 유형이 있으며, 그중 하나가 비궤양성 IC로, IC 환자의 90%에서 나타납니다. 이것은 '글로메라레이션'라고 불리는 바늘 끝만큼 미세한 출혈이 특징입니다. 또 다른 유형은 궤양성 과민성 대장 증후군으로, 전체 환자의 약 5-10%를 차지합니다. 이는 주로 훈나 궤양이나 방광벽에 출혈을 동반하는 병변을 특징으로 합니다. 훈나 궤양은 '훈나 병변' 또는 '훈나 반점'라고도 불리며, IC의 하위 유형 중 하나이지만, 일반적인 의미의 궤양은 아닙니다. 이는 방광벽에서 볼 수 있는 특징적인 염증 부위이며, '전형적인' IC의 형태를 특징짓는 것으로, IC 환자의 약 5-10%에서만 나타납니다.
시장 역학
간질성 방광염의 높은 유병률이 전 세계 간질성 방광염 치료제 시장을 주도하고 있습니다. 간질성 방광염을 앓고 있는 환자는 하부 요로 문제나 방광통 등의 증상을 경험합니다. 이 질환은 여성에게서 흔히 나타납니다. Patnaik 등(2017)에 따르면 유병률 추정 결과 북미에서는 여성 10만 명당 45명, 남성 10만 명당 8명이 IC로 진단받는 것으로 나타났습니다.
본 조사의 주요 특징 :
- 이 조사에서는 다양한 부문의 잠재적 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 이 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 시장 전략)를 바탕으로, 전 세계 간질성 방광염 치료제 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 이 '세계의 간질성 방광염 치료제 시장 보고서'는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 간질성 방광염 치료제 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 간질성 방광염 치료제 시장 : 약제 클래스별, 2021-2033년
제5장 세계의 간질성 방광염 치료제 시장 : 유형별, 2021-2033년
제6장 세계의 간질성 방광염 치료제 시장 : 투여 경로별, 2021-2033년
제7장 세계의 간질성 방광염 치료제 시장 : 유통 채널별, 2021-2033년
제8장 세계의 간질성 방광염 치료제 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 섹션
KSA 26.07.08Interstitial Cystitis Drugs Market is estimated to be valued at USD 287.6 Mn in 2026 and is expected to reach USD 464.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 287.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.10% | 2033 Value Projection: | USD 464.8 Mn |
Interstitial Cystitis (IC) also called as painful bladder syndrome, is a chronic condition causing bladder pressure, bladder pain, and sometimes pelvic pain. The pain ranges from mild discomfort to severe levels. The bladder expands until it is full and then gives signal to the brain that it is time to urinate, communicating through pelvic nerves. With IC, these signals get mixed up and then patient feels the need to urinate more often and with smaller volumes of urine than most people. The IC disease most often affects women and can has a long-lasting impact on the quality of life. Although there is no cure, medications, and other therapies may offer some relief.
There are two types of IC such as non-ulcerative IC, which is found in 90% of the population suffering from IC. It is characterized by pinpoint hemorrhages called glomerulations. Another type of IC is Ulcerative IC, which comprises of about 5-10% of the patient population. It is mainly characterized by Hunner's ulcers and the patches that bleed on bladder walls. Hunner's ulcers, also called "Hunner's lesions" or "Hunner's patches", are a sub type of IC and are not ulcers in the usual sense. They are distinctive areas of inflammation on the bladder wall that characterize the "classic" form of IC, and it affects only about 5 to 10 percent of patients suffering from IC.
Market Dynamics
The high prevalence of interstitial cystitis is driving the global interstitial cystitis drugs market. Patients suffering from interstitial cystitis experience symptoms such as lower urinary tract issues and bladder pain. Women are highly affected by this condition. According to Patnaik et al., 2017, prevalence estimates suggest that 45 per 100,000 females and 8 per 100,000 men are diagnosed with IC in North America.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global interstitial cystitis drugs market based on the following parameters - Company Highlights, Product Portfolio, Key Highlights, Financial Performance, and Market Strategies.
- Key companies covered as a part of this study include Bayer AG, Eli Lilly and Co., Johnson & Johnson, Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., Seikagaku Corp., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global interstitial cystitis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interstitial cystitis drugs market
Detailed Segmentation:
- Global Interstitial Cystitis Drugs market, By Drugs (Revenue, USD Mn, 2021 - 2033)
- Pentosan Polysulfate Sodium
- Dimethyl Sulfoxide
- Others
- Global Interstitial Cystitis Drugs market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
- Oral Therapy
- Intravesical Therapy
- Global Interstitial Cystitis Drugs market, By End User (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Interstitial Cystitis Drugs Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- By Drugs
- Pentosan Polysulfate Sodium
- Dimethyl Sulfoxide
- Others
- By Route of Administration
- Oral Therapy
- Intravesical Therapy
- By End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- U.S.
- Canada
- By Drugs
- Latin America
- By Drugs
- Pentosan Polysulfate Sodium
- Dimethyl Sulfoxide
- Others
- By Route of Administration
- Oral Therapy
- Intravesical Therapy
- By End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drugs
- Europe
- By Drugs
- Pentosan Polysulfate Sodium
- Dimethyl Sulfoxide
- Others
- By Route of Administration
- Oral Therapy
- Intravesical Therapy
- By End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Drugs
- Asia Pacific
- By Drugs
- Pentosan Polysulfate Sodium
- Dimethyl Sulfoxide
- Others
- By Route of Administration
- Oral Therapy
- Intravesical Therapy
- By End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Drugs
- Middle East
- By Drugs
- Pentosan Polysulfate Sodium
- Dimethyl Sulfoxide
- Others
- By Route of Administration
- Oral Therapy
- Intravesical Therapy
- By End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- By Drugs
- Africa
- By Drugs
- Pentosan Polysulfate Sodium
- Dimethyl Sulfoxide
- Others
- By Route of Administration
- Oral Therapy
- Intravesical Therapy
- By End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- South Africa
- Central Africa
- North Africa
- By Drugs
- Company Profiles
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Co.
- Johnson & Johnson
- Mylan NV
- Novartis AG
- Perrigo Co. Plc
- Pfizer Inc.
- Seikagaku Corp.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Drug Launch with Historic Roadmap
- Epidemiology
- Pipeline Analysis
- Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Interstitial Cystitis Drugs Market, By Drug Class, 2021-2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Non-steroidal Anti-inflammatory Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
- Tricyclic Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
- Pentosan Polysulfate Sodium (Elmiron)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
- Dimethyl Sulfoxide (DMSO)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
- Others (Anti-histamines, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
5. Global Interstitial Cystitis Drugs Market, By Type, 2021-2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Non-ulcerative
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
- Ulcerative
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
6. Global Interstitial Cystitis Drugs Market, By Route of Administration, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
- Intravesical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
7. Global Interstitial Cystitis Drugs Market, By Distribution Channel, 2021-2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
8. Global Interstitial Cystitis Drugs Market, By Region, 2021-2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Type, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021-2033, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Type, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021-2033, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Type, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021-2033, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Type, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021-2033, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Type, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021-2033, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Type, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2021-2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/ Region, 2021-2033, (US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Hyloris Pharmaceuticals SA
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- TAGCyx Biotechnologies
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- KYORIN Pharmaceutical Co., Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- PureTech Health
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Vaneltix
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Red Leaf Medical Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Eli Lilly and Co.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Johnson & Johnson (Janssen Pharmaceuticals)
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Mylan NV (Viatris Inc.)
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Perrigo Co. Plc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Seikagaku Corp.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- ImprimisRx (Harrow Health, Inc.)
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- AbbVie Inc.
10. Section
- References
- Research Methodology
- About us and Sales Contact
